Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor.

Kratochwil NA, Triyatni M, Mueller MB, Klammers F, Leonard B, Turley D, Schmaler J, Ekiciler A, Molitor B, Walter I, Gonsard PA, Tournillac CA, Durrwell A, Marschmann M, Jones R, Ullah M, Boess F, Ottaviani G, Jin Y, Parrott NJ, Fowler S.

J Pharmacol Exp Ther. 2018 May;365(2):237-248. doi: 10.1124/jpet.117.245712. Epub 2018 Feb 16.

PMID:
29453199
2.

Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling.

Kratochwil NA, Meille C, Fowler S, Klammers F, Ekiciler A, Molitor B, Simon S, Walter I, McGinnis C, Walther J, Leonard B, Triyatni M, Javanbakht H, Funk C, Schuler F, Lavé T, Parrott NJ.

AAPS J. 2017 Mar;19(2):534-550. doi: 10.1208/s12248-016-0019-7. Epub 2017 Jan 3.

PMID:
28050713
3.

Assembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathway.

Triyatni M, Berger EA, Saunier B.

World J Hepatol. 2016 Jul 8;8(19):796-814. doi: 10.4254/wjh.v8.i19.796.

4.

Correction: Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B.

Fletcher SP, Chin DJ, Gruenbaum L, Bitter H, Rasmussen E, Ravindran P, Swinney DC, Birzele F, Schmucki R, Lorenz SH, Kopetzki E, Carter J, Triyatni M, Thampi LM, Yang J, AlDeghaither D, Murreddu MG, Cote P, Menne S.

PLoS Pathog. 2016 Mar 29;12(3):e1005541. doi: 10.1371/journal.ppat.1005541. eCollection 2016 Mar. No abstract available.

5.

Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B.

Fletcher SP, Chin DJ, Gruenbaum L, Bitter H, Rasmussen E, Ravindran P, Swinney DC, Birzele F, Schmucki R, Lorenz SH, Kopetzki E, Carter J, Triyatni M, Thampi LM, Yang J, AlDeghaither D, Murreddu MG, Cote P, Menne S.

PLoS Pathog. 2015 Sep 9;11(9):e1005103. doi: 10.1371/journal.ppat.1005103. eCollection 2015 Sep. Erratum in: PLoS Pathog. 2016 Mar;12(3):e1005541. Murredu, Marta G [corrected to Murreddu, Marta G].

6.

Scalable spheroid model of human hepatocytes for hepatitis C infection and replication.

Ananthanarayanan A, Nugraha B, Triyatni M, Hart S, Sankuratri S, Yu H.

Mol Pharm. 2014 Jul 7;11(7):2106-14. doi: 10.1021/mp500063y. Epub 2014 May 6.

PMID:
24761996
7.

A new model to produce infectious hepatitis C virus without the replication requirement.

Triyatni M, Berger EA, Saunier B.

PLoS Pathog. 2011 Apr;7(4):e1001333. doi: 10.1371/journal.ppat.1001333. Epub 2011 Apr 14. Review.

8.
9.

Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry.

Triyatni M, Saunier B, Maruvada P, Davis AR, Ulianich L, Heller T, Patel A, Kohn LD, Liang TJ.

J Virol. 2002 Sep;76(18):9335-44.

10.

Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.

Triyatni M, Vergalla J, Davis AR, Hadlock KG, Foung SK, Liang TJ.

Virology. 2002 Jun 20;298(1):124-32.

11.

Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles.

Cerino A, Meola A, Segagni L, Furione M, Marciano S, Triyatni M, Liang TJ, Nicosia A, Mondelli MU.

J Immunol. 2001 Oct 1;167(7):3878-86.

12.

Sequence comparison of an Australian duck hepatitis B virus strain with other avian hepadnaviruses.

Triyatni M, Ey P, Tran T, Le Mire M, Qiao M, Burrell C, Jilbert A.

J Gen Virol. 2001 Feb;82(Pt 2):373-8.

PMID:
11161276
13.

Protective efficacy of DNA vaccines against duck hepatitis B virus infection.

Triyatni M, Jilbert AR, Qiao M, Miller DS, Burrell CJ.

J Virol. 1998 Jan;72(1):84-94.

Supplemental Content

Loading ...
Support Center